ability to increase net sales through the Company's distribution channels,
insufficient quantity of new account conversions, insufficient cash to fund
operations, scale up production to meet delivery obligations, delay in
developing new products and receiving FDA approval for such new products
and other factors discussed in the Company's filings with the Securities
and Exchange Commission.
CONTACT: Marcia McHaffie, Encision Inc., 303-444-2600,
mmchaffie@encision.com
'/>"/>SOURCE Encision Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 Related biology technology :1.
Sagent Pharmaceuticals Launches Cefazolin for Injection, USP2.
BioElectronics Launches 1 Day Breast Augmentation Recovery Kit3.
Allen Institute for Brain Science Launches Three New Landmark Atlas Projects Focusing on the Human Brain, Developing Brain and Spinal Cord4.
Altogen Biosystems Launches Custom Biotechnology Research Services: Generation of Stable Cell Lines and RNAi Cell Transfection Services5.
Moleac Launches NeuroAid10(TM) in the United States6.
Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients7.
MultiVu Video Feed: Johnson & Johnson Diabetes Institute, LLC Launches New Training Center to Improve Community-Based Diabetes Care8.
BioCrossroads Launches www.biocrossroadslinx.com and Releases Report on Biopharma Discovery and Development Contract Services9.
ChemAxon Launches Marvin and JChem Version 5: Better User Experience, Better Integration, More Flexibility and Higher Performance10.
Coalition for a Competitive Pharmaceutical Market Launches New Print Ad Campaign Highlighting Need for Meaningful Biogenerics Legislation11.
Addressing the Pharmacist Shortage: Medco Labor Coalition(TM) Launches National Scholarship Program to Support the Development of the Next Generation of Pharmacists